PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-13.71%
Negative net income growth while VET stands at 890.31%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
17.57%
D&A growth well above VET's 2.11%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
80.68%
Well above VET's 45.37% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-720.43%
Negative yoy working capital usage while VET is 43.45%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-162.94%
Negative yoy while VET is 11.17%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-45.29%
Negative yoy CFO while VET is 45.21%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
21.44%
Some CapEx rise while VET is negative at -189.52%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-641.12%
We reduce yoy other investing while VET is 32807.44%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-226.89%
We reduce yoy invests while VET stands at 454.14%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-2582.77%
We cut debt repayment yoy while VET is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-61.20%
Negative yoy issuance while VET is 710.37%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
94.45%
Buyback growth of 94.45% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.